![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Preliminary Results From a Phase 2 Study Evaluating VIR-2218 Alone and in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis B Infection
|
|
|
AASLD 2021 Nov 12-15
Man-Fung Yuen1, Young-Suk Lim2, Daniel Cloutier3, Vaidehi Thanawala3, Ling Shen3, Andre Arizpe3, Chin Tay3, Sneha Gupta3, Andrea L Cathcart3, Carey Hwang3, Phillip S. Pang3, and Edward Gane4
1The University of Hong Kong, Hong Kong, China; 2University of Ulsan College of Medicine, Seoul, Korea; 3Vir Biotechnology Inc., San Francisco, California, USA; 4University of Auckland, Auckland, New Zealand
![1115211](../images/111521/111521-7/1115211.gif)
![1115212](../images/111521/111521-7/1115212.gif)
![1115213](../images/111521/111521-7/1115213.gif)
![1115214](../images/111521/111521-7/1115214.gif)
![1115215](../images/111521/111521-7/1115215.gif)
![1115216](../images/111521/111521-7/1115216.gif)
![1115217](../images/111521/111521-7/1115217.gif)
![1115218](../images/111521/111521-7/1115218.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|